Pharmalucence formally CIS-US Inc.
Careers News Resources Contact  
    Company
 
  Manufacturing Capabilities
 
  Facility Details 
 
  Nuclear Medicine Products
 
 
 





Company News
Come See Us
Pharmalucence
Company News


September 29, 2017

Our original Bedford MA Manufacturing facility has closed.
With all Pharmalucence products either fully transferred or in process for transfer to our Billerica MA facility, we have closed our original facility in Bedford MA.

READ MORE



February 14, 2017

New Second Lyophilzer Installation Project Begins
Pharmalucence is installing a second 180 sq. ft. IMA lyophilizer, which will double our capacity at our Billerica MA facility.

READ MORE



April 25, 2016

Pharmalucence receives FDA approval to commence manufacturing operations at its Billerica MA facility
The Pharmalucence manufacturing site located at 29 Dunham Rd., Billerica, MA has received FDA approval for drug product aseptic fill-finish manufacturing operations. Our Tc 99m Sulfur Colloid Kit will be the first product manufactured at this new facility. Pharmalucence is now in the process of transferring the manufacturing process for all of its other injectable products to this site.

READ MORE



March 24, 2015

2015 ISPE Facility of the Year Award Winners
Pharmalucence receives Honorable Mention for their new parenteral facility from the International Society for Pharmaceutical Engineering (ISPE).

READ MORE



July 18, 2014

Pharmalucence acquired by Sun Pharma July 15, 2014
Please see the attached announcement for details.

READ MORE



May 13, 2014

Pharmalucence announces divestiture of IBL 437C Blood Irradiator Service
MikRon Inc. to assume IBL 437C service business effective August 6, 2014. To contact MikRon for IBL 437C service, please contact them at (508) 589-4600 or email Jim Thomson at Jim@mikroninc.com.

READ MORE



April 30, 2014

Pharmalucence Aseptic Fill and Finish Facility Milestone - DMF Submission
Pharmalucence submits its DMF (Drug Master File) to FDA on Tuesday April 29, 2014.

READ MORE



December 09, 2013

Pharmalucence announces manufacturing contract at its new parenteral manufacturing facility in Billerica, MA
Pharmalucence, Inc. announced that it has entered into an agreement with Lantheus Medical Imaging, Inc. to serve as a contract manufacturer of DEFINITY® Vial for (Perflutren Lipid Microsphere) Injectable Suspension for contrast-enhanced echocardiography.

READ MORE



December 17, 2012

Pharmalucence to co-sponsor Aseptic Drug Manufacturing Symposium March 11-13, 2013
In partnership with Bosch, Pharmalucence is inviting Drug Manufacturing professionals from across the U.S. to attend "Innovation Symposium 2013, Injectable Drug Manufacturing" at the Marriott Hotel in Burlington MA.

READ MORE



November 20, 2012

Pharmalucence recognized with award from MassEcon.
Pharmalucence has been named as a "Rising Star" award winner for the Team Massachusetts Economic Impact Awards, awarded annually by MassEcon (Massachusetts Alliance for Economic Development).

READ MORE



  Page 1 of 3  

September 17, 2012

FDA grants Orphan Drug designation status to Sulfur Colloid.
Pharmalucence receives FDA notification that Sulfur Colloid Injection (SCI) has been granted Orphan Drug designation status and seven years of market exclusivity for its use in lymph node localization in melanoma patients.

READ MORE



August 27, 2012

Pharmalucence has been selected as one of 19 finalists for the 9th annual MASSECON 2012.


READ MORE



August 16, 2012

Pharmalucence receives FDA approval for use of Sulfur Colloid Injection (SCI) to locate lymph nodes in malignant melanoma patients.


READ MORE



May 03, 2012

“Making it in Massachusetts: A Small Company’s Road to the CMO Market” at Interphex 2012.
Glenn Alto, President and CEO, and Ed Connolly, COO, to present “Making it in Massachusetts: A Small Company’s Road to the CMO Market” at Interphex 2012

READ MORE



February 22, 2012

The Massachusetts Life Sciences Center (MLSC) named Pharmalucence as one of 28 Massachusetts Life Sciences companies to receive a tax incentive in return for creating new jobs in the industry.
The Massachusetts Life Sciences Center announced today that has awarded $21.2 million in tax incentives to 28 life sciences companies.

READ MORE



January 23, 2012

Pharmalucence begins operations at our new Corporate HeadQuarters in Billerica Massachusetts.
While manufacturing operations and personnel remain in Bedford MA while our new facility project continues, all administrative staff has now relocated to 29 Dunham Road, Billerica, MA 01821. Our toll free number remains 1-800-221-7554, but some employee direct dial numbers have changed.

READ MORE



December 27, 2011

Pharmalucence Supplemental New Drug Application (sNDA) for the use of Sulfur Colloid Injection (SCI) in the localization of lymph nodes in melanoma patients has been accepted for review by FDA.


READ MORE



July 29, 2011

Pharmalucence partners with Robert Bosch Packaging Technology for new Drug Production Facility.


READ MORE



July 25, 2011

Pharmalucence receives FDA approval expanding the route of administration and use of its Sulfur Colloid Injection (SCI).


READ MORE



July 07, 2011

Pharmalucence partners with Integrated Project Services for design and construction of new facility.


READ MORE



  Page 2 of 3  

March 02, 2011

Pharmalucence receives FDA approval expanding the route of administration and use of its Sulfur Colloid Injection (SCI) to include location of lymph nodes in breast cancer patients.


READ MORE



June 03, 2010

Pharmalucence Announces Purchase of New Property in Billerica MA. To be Developed into New Corporate Headquarters and State-of-the-Art Drug Manufacturing Facility, beginning Summer 2010.


READ MORE



July 10, 2009

Pharmalucence Announces Approval of Generic version of Cardiolite® Kit for the Preparation of Technetium Tc-99m Sestamibi Injection.


READ MORE



August 11, 2008

Pharmalucence Announces Divestiture of AeroTech® Products to Biodex Medical Systems.


READ MORE



January 30, 2008

Pharmalucence Announces Approval of Generic version of Choletec® Kit for the Preparation of Technetium Tc-99m Mebrofenin.


READ MORE



  Page 3 of 3  

For more information, please contact:
John Felock
Director; Sales, Marketing and Customer Service
1-781-687-1245
jfelock@pharmalucence.com



29 Dunham Road, Billerica, MA 01821 | Telephone: 781-275-7120    © Pharmalucence Inc. All rights reserved.
HOME   |   SITE MAP   |   LEGAL STATEMENT   |   PRIVACY POLICY   |